BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Leopold, J. A., Maron, B. A., & Loscalzo, J. The application of big data to cardiovascular disease: Paths to precision medicine. The Journal of Clinical Investigation, 130(1), 29–38. Added by: Dr. Enrique Feoli (04/05/2022, 20:26) Last edited by: Dr. Enrique Feoli (04/05/2022, 20:28) |
 |
| Resource type: Journal Article DOI: 10.1172/JCI129203 ID no. (ISBN etc.): 0021-9738 BibTeX citation key: Leopold View all bibliographic details  |
Categories: BioAcyl Corp Subcategories: Non communicable diseases Creators: Leopold, Loscalzo, Maron Collection: The Journal of Clinical Investigation |
Views: 1/232
|
| Abstract |
|
Advanced phenotyping of cardiovascular diseases has evolved with the application of high-resolution omics screening to populations enrolled in large-scale observational and clinical trials. This strategy has revealed that considerable heterogeneity exists at the genotype, endophenotype, and clinical phenotype levels in cardiovascular diseases, a feature of the most common diseases that has not been elucidated by conventional reductionism. In this discussion, we address genomic context and (endo)phenotypic heterogeneity, and examine commonly encountered cardiovascular diseases to illustrate the genotypic underpinnings of (endo)phenotypic diversity. We highlight the existing challenges in cardiovascular disease genotyping and phenotyping that can be addressed by the integration of big data and interpreted using novel analytical methodologies (network analysis). Precision cardiovascular medicine will only be broadly applied to cardiovascular patients once this comprehensive data set is subjected to unique, integrative analytical strategies that accommodate molecular and clinical heterogeneity rather than ignore or reduce it.
|